Ticker LaunchUplisting · LEXX
Lexaria Bioscience Corp.
Formerly Lexaria Corp.; LEXARIA CORP.
Lexaria Bioscience Corp. (LEXX), already reporting to the SEC, moved up to Nasdaq Capital Market on Jan 14, 2021 with an offering at $5.25 per share raising $9.6M. Sichenzia Ross Ference Carmel advised the company and Ellenoff Grossman & Schole advised the underwriters.
Lexaria Bioscience Corp. is a Nevada company that develops and patents DehydraTECH, a technology for improving oral delivery of active ingredients and drugs. Its research covers cannabinoids, nicotine, vitamins, NSAIDs, hormones, phosphodiesterase inhibitors and antivirals.
- Status
- Uplisting
- Ticker
- LEXX
- Exchange
- Nasdaq Capital Market
- Listed
- Jan 14, 2021
- Price
- $5.25
- Raised
- $9.6M
- Market cap at IPO price
- $25.4M
- First filed
- Jul 21, 2011
- Company counsel
- Sichenzia Ross Ference Carmel
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Biotech & pharma
- Country / state
- British Columbia, Canada
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 21, 2011
- Latest amendment Jan 7, 2021
- Final prospectus (424B4) Jan 14, 2021
- All filings on EDGAR CIK 1348362
Other Biotech & pharma uplistings in 2021
- Evotec SEEVO · Nov 5, 2021 · $435M
- Zivo Bioscience, Inc.ZIVO · Jun 1, 2021 · $13.8M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- Protagenic Therapeutics, Inc.\newPTIX · Apr 28, 2021 · $13.2M
- GT Biopharma, Inc.GTBP · Feb 12, 2021 · $23.6M
- Zevra Therapeutics, Inc.KMPH · Jan 11, 2021